The combined deleterious effects of glucotoxicity and lipotoxicity, referred to as glucolipotoxicity, eventually causes β-cell failure characteristic of T2DM.9 Chronic hyperglycemia as found in obesity-induced insulin resistance promotes the development of glucotoxicity.10 Several peptide hormones secreted by the endocrine pancreas, gut, adipocytes, and liver modulate insulin activity to maintain glucose homeostasis and fat amounts; these hormones are considered promising leads in the development of therapies against T2DM and fatty liver or pancreas disease.11, 12. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.